Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders (ROP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00447733|
Recruitment Status : Completed
First Posted : March 15, 2007
Last Update Posted : March 26, 2012
|Condition or disease||Intervention/treatment||Phase|
|Anxiety Disorders Mood Disorders Substance Use Disorders||Behavioral: Integrated mental health and substance use treatment Behavioral: Treatment as usual||Not Applicable|
Patients with mental disorders and co-occuring substance use disorders are characterized by high suicide rates, high treatment drop-out rates and long-lasting interpersonal, work, school, health and legal problems. Because mental disorders and substance use disorders co-exist and interact, it may be important to provide a treatment that addresses the substance misuse and mental health problems in an integrated and comprehensive way. Additionally, the health services for patients with mental health and substance use disorders are usually provided by different services and health professionals that rarely cooperate or have qualifications on both kinds of disorders. This also calls for an integration of the services on an organizational level. This approach of integrating services and treatment approaches for both diseases in a comprehensive way is called Integrated Treatment. Several studies have shown that Integrated Treatment is effective in treating the comorbidity of severe mental illness and substance use disorders. The over-all aim of this study is to evaluate the effects of evidence-based Integrated Treatment in anxiety and/or depression with co-occurring substance use disorders. The effects of the treatment will be assesses on changes in substance use and psychopathology.
Comparison: patients receiving treatment-as-usual or non-manualized treatment at general mental health outpatients clinics.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||76 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders|
|Study Start Date :||March 2007|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||December 2010|
Experimental: Integrated treatment
Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
Behavioral: Integrated mental health and substance use treatment
Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
Active Comparator: Treatment as usual
Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
Behavioral: Treatment as usual
Non-standardized psychiatric outpatient treatment
- The Symptom Check List 90 (SCL90-r), The Alcohol Use Disorder Identification Test (AUDIT), The Drug Use Disorder Identification Test (DUDIT). [ Time Frame: Change during 6 and 12 months follow-up ]
We use the SCL-90r to measure symptoms in regard to anxiety, depression and the General Severity Index.
We use the AUDIT and the DUDIT to measure changes in the use of alcohol and illegal drugs respectively.
- The Addiction Severity Index (Europ ASI) [ Time Frame: Change during 6 and 12 months follow up ]The Addiction Severity Index (Europ ASI) is used to assess changes in the use of alcohol and illegal substances during the course of the trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00447733
|Principal Investigator:||Rolf W. Gråwe, Ph.D||Alcohol and Drug Treatment Health Trust in Central Norway; Norwegian Centre of Addiction Research, University of Oslo|